Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Change in Accured Expenses (2022 - 2026)

Sagimet Biosciences' Change in Accured Expenses history spans 5 years, with the latest figure at $637000.0 for Q1 2026.

  • Quarterly Change in Accured Expenses fell 81.21% to $637000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.8 million through Mar 2026, down 155.87% year-over-year, with the annual reading at $929000.0 for FY2025, 202.43% up from the prior year.
  • Change in Accured Expenses came in at $637000.0 for Q1 2026, up from -$4.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.4 million in Q1 2025 to a low of -$4.0 million in Q4 2025.
  • The 5-year median for Change in Accured Expenses is $320000.0 (2023), against an average of $55266.7.
  • The largest YoY upside for Change in Accured Expenses was 533.5% in 2025 against a maximum downside of 994.82% in 2025.
  • Sagimet Biosciences' Change in Accured Expenses stood at -$1.0 million in 2022, then soared by 131.84% to $320000.0 in 2023, then soared by 38.75% to $444000.0 in 2024, then tumbled by 994.82% to -$4.0 million in 2025, then surged by 116.03% to $637000.0 in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Change in Accured Expenses are $637000.0 (Q1 2026), -$4.0 million (Q4 2025), and $1.6 million (Q3 2025).